TLR stimulation modifies BLyS receptor expression in follicular and marginal zone B cells

Journal of Immunology

Volumn 178, Issue 12, 2007, Pages 7531-7539

  Treml, Laura S ^a   Carlesso, Gianluca ^b   Hoek, Kristen L ^b   Stadanlick, Jason E ^a   Kambayashi, Taku ^a   Bram, Richard J ^c   Cancro, Michael P ^a   Khan, Wasif N ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLYS RECEPTOR; CALCIUM ION; CYCLOPHILIN; CYCLOPHILIN LIGAND INTERACTOR; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN P50; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR REL; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CALCIUM TRANSPORT; CELL DIFFERENTIATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION;

EID: 34250169733     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.12.7531     Document Type: Article

References (57)

1. Harless Smith, S. M., and M. P. Cancro. 2003. BLyS: the pivotal determinant of peripheral B cell selection and lifespan. Curr. Pharm. Des. 9: 1833-1847.
2. Mackay, F., P. Schneider, P. Rennert, and J. Browning. 2003. BAFF AND APRIL: a tutorial on B cell survival. Annu. Rev. Immunol. 21: 231-264.
3. Schneider, P., F. MacKay, V. Steiner, K. Hofmann, J. L. Bodmer, N. Holler, C. Ambrose, P. Lawton, S. Bixler, H. Acha-Orbea, et al. 1999. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J. Exp. Med. 189: 1747-1756.
4. Hsu, B. L., S. M. Harless Smith, R. C. Lindsley, D. M. Hilbert, and M. P. Cancro. 2002. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J. Immunol. 168: 5993-5996.
5. Moore, P. A., O. Belvedere, A. Orr, K. Pieri, D. W. LaFleur, P. Feng, D. Soppet, M. Charters, R. Gentz, D. Parmelee, et al. 1999. BLyS: member of the minor necrosis factor family and B lymphocyte stimulator. Science 285: 260-263.
6. Mackay, F., S. A. Woodcock, P. Lawton, C. Ambrose, M. Baetscher, P. Schneider, J. Tschopp, and J. L. Browning. 1999. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 190: 1697-1710.
7. Gross, J. A., S. R. Dillon, S. Mudri, J. Johnston, A. Littau, R. Roque, M. Rixon, O. Schou, K. P. Foley, H. Haugen, et al. 2001. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease-impaired B cell maturation in mice lacking BLyS. Immunity 15: 289-302.
8. Lentz, V. M., M. P. Cancro, F. E. Nashold, and C. E. Hayes. 1996. Bcmd governs recruitment of new B cells into the stable peripheral B cell pool in the A/WySnJ mouse. J. Immunol. 157: 598-606.
9. Lentz, V. M., C. F. Hayes, and M. P. Cancro. 1998. Bcmd decreases the life span of B-2 but not B-1 cells in A/WySnJ mice. J. Immunol. 160: 3743-3747.
10. Harless Smith, S. M., V. M. Lentz, A. P. Sah, B. L. Hsu, K. Clise-Dwyer, D. M. Hilbert, C. E. Hayes, and M. P. Cancro. 2001. Competition for BLyS-mediated signaling through Bcmd/BR3 regulates peripheral B lymphocyte numbers. Curr. Biol. 11: 1986-1989.
11. Yan, M., J. R. Brady, B. Chan, W. P. Lee, B. Hsu, S. M. Harless Smith, M. Cancro, I. S. Grewal, and V. M. Dixit. 2001. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe β cell deficiency. Curr. Biol. 11: 1547-1552.
12. Thompson, J. S., S. A. Bixler, F. Qian, K. Vora, M. L. Scott, T. G. Cachero, C. Hession, P. Schneider, I. D. Sizing, C. Mullen, et al. 2001. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293: 2108-2111.
13. Zhang, J., V. Roschke, K. P. Baker, Z. Wang, G. S. Alarcon, B. J. Fessler, H. Bastian, R. P. Kimberly, and T. Zhou. 2001. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J. Immunol. 166: 6-10.
14. Mackay, I. R., J. Groom, and C. R. Mackay. 2002. Levels of BAFF in serum in primary biliary cirrhosis and autoimmune diabetes. Autoimmunity 35: 551-553.
15. + T cells: lessons from HIV-infected patients. Clin. Immunol. 104: 115-122.
16. Stohl, W. 2002. Systemic lupus erythematosus: a blissless disease of too much BLyS (B lymphocyte stimulator) protein. Curr. Opin. Rheumatol. 14: 522-528.
17. Batten, M., J. Groom, T. G. Cachero, F. Qian, P. Schneider, J. Tschopp, J. L. Browning, and F. Mackay. 2000. BAFF mediates survival of peripheral immature B lymphocytes. J. Exp. Med. 192: 1453-1466.
18. Rolink, A. G., J. Tschopp, P. Schneider, and F. Melchers. 2002. BAFF is a survival and maturation factor for mouse B cells. Eur. J. Immunol. 32: 2004-2010.
19. Schneider, P., H. Takatsuka, A. Wilson, F. Mackay, A. Tardivel, S. Lens, T. G. Cachero, D. Finke, F. Beermann, and J. Tschopp. 2001. Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J. Exp. Med. 194: 1691-1697.
20. Miller, D. J., and C. E. Hayes. 1991. Phenotypic and genetic characterization of a unique B lymphocyte deficiency in strain A/WySnJ mice. Eur. J. Immunol. 21: 1123-1130.
21. Schiemann, B., J. L. Gommerman, K. Vora, T. G. Cachero, S. Shulga-Morskaya, M. Dobles, E. Frew, and M. L. Scott. 2001. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293: 2111-2114.
22. Seshasayee, D., P. Valdez, M. Yan, V. M. Dixit, D. Tumas, and I. S. Grewal. 2003. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 18: 279-288.
23. Yan, M., H. Wang, B. Chan, M. Roose-Girma, S. Erickson, T. Baker, D. Tumas, I. S. Grewal, and V. M. Dixit. 2001. Activation and accumulation of B cells in TACI-deficient mice. Nat. Immunol. 2: 638-643.
24. O'Connor, B. P., V. S. Raman, L. D. Erickson, W. J. Cook, L. K. Weaver, C. Ahonen, L. L. Lin, G. T. Mantchev, R. J. Bram, and R. J. Noelle. 2004. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199: 91-98.
25. Smith, S. H., and M. P. Cancro. 2003. Cutting edge: B cell receptor signals regulate BLyS receptor levels in mature B cells and their immediate progenitors. J. Immunol. 170: 5820-5823.
26. Walmsley, M. J., S. K. Ooi, L. F. Reynolds, S. H. Smith, S. Ruf, A. Mathiot, L. Vanes, D. A. Williams, M. P. Cancro, and V. L. Tybulewicz. 2003. Critical roles for Rac1 and Rac2 GTPases in B cell development and signaling. Science 302: 459-462.
27. Moritoki, Y., Z. X. Lian, Y. Ohsugi, Y. Ueno, and M. E. Gershwin. 2006. B cells and autoimmune liver diseases. Autoimmun. Rev. 5: 449-457.
28. Meylan, E., and J. Tschopp. 2006. Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol. Cell 22: 561-569.
29. Vos, Q., A. Lees, Z. Q. Wu, C. M. Snapper, and J. J. Mond. 2000. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol. Rev. 176: 154-170.
30. Alugupalli, K. R., S. Akira, E. Lien, and J. M. Leong. 2007. MyD88- and Bruton's tyrosine kinase-mediated signals are essential for T cell-independent pathogen-specific IgM responses. J. Immunol. 178: 3740-3749.
31. Melchers, F., V. Braun, and C. Galanos. 1975. The lipoprotein of the outer membrane of Escherichia coli: a B-lymphocyte mitogen. J. Exp. Med. 142: 473-482.
32. Krieg, A. M., A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A. Koretzky, and D. M. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549.
33. Takeda, K., and S. Akira. 2004. TLR signaling pathways. Semin. Immunol. 16: 3-9.
34. Akira, S., and K. Takeda. 2004. Toll-like receptor signalling. Nat. Rev. Immunol. 4: 499-511.
35. Doyle, S. L., and L. A. O'Neill. 2006. Toll-like receptors: from the discovery of NFκB to new insights into transcriptional regulations in innate immunity. Biochem. Pharmacol. 72: 1102-1113.
36. Adachi, O., T. Kawai, K. Takeda, M. Matsumoto, H. Tsutsui, M. Sakagami, K. Nakanishi, and S. Akira. 1998. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9: 143-150.
37. Liou, H. C., Z. Jin, J. Tumang, S. Andjelic, K. A. Smith, and M. L. Liou, 1999. c-Rel is crucial for lymphocyte proliferation but dispensable for T cell effector function. Int. Immunol. 11: 361-371.
38. von Bulow, G. U., J. M. van Deursen, and R. J. Bram. 2001. Regulation of the T-independent humoral response by TACI. Immunity 14: 573-582.
39. Poltorak, A., X. H., I. Smirnova, M. Y. Liu, C. Van Huffel, X. Du, D. Birdwell, E. Alejos, M. Silva, C. Galanos, et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282: 2085-2088.
40. Yamamoto, M., S. Sato, H. Hemmi, K. Hoshino, T. Kaisho, H. Sanjo, O. Takeuchi, M. Sugiyama, M. Okahe, K. Takeda, and S. Akira. 2003. Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science 301: 640-643.
41. Petro, J. B., R. M. Gerstein, J. Lowe, R. S. Carter, N. Shinners, and W. N. Khan, 2002. Transitional type 1 and 2 B lymphocyte subsets are differentially responsive to antigen receptor signaling. J. Biol. Chem. 277: 48009-48019.
42. Kambayashi, T., R. P. Wallin, and H. G. Ljunggren. 2001. cAMP-elevating agents suppress dendritic cell function. J. Leukocyte Biol. 70: 903-910.
43. Silverman, M. A., J. Shoag, J. Wu, and G. A. Koretzky. 2006. Disruption of SLP-76 interaction with Gads inhibits dynamic clustering of SLP-76 and FCεRI signaling in mast cells. Mol. Cell. Biol. 26: 1826-1838.
44. Khare, S. D., I. Sarosi, X. Z. Xia, S. McCabe, K. Miner, I. Solovyev, N. Hawkins, M. Kelley, D. Chang, G. Van, et al. 2000. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc. Natl. Acad. Sci. USA 97: 3370-3375.
45. Do, R. K., and S. Chen-Kiang. 2002. Mechanism of BLyS action in B cell immunity. Cytokine Growth Factor Rev. 13: 19-25.
46. Fitzgerald, K. A., and Z. J. Chen. 2006. Sorting out Toll signals. Cell 125: 834-836.
47. Hirotani, T., M. Yamamoto, Y. Kumagai, S. Uematsu, I. Kawase, O. Takeuchi, and S. Akira. 2005. Regulation of lipopolysaccharide-inducible genes by MyD88 and Toll/IL-1 domain containing adaptor inducing IFN-β. Biochem. Biophys. Res. Commun. 328: 383-392.
48. Ng, L. G., C. H. Ng, B. Woehl, A. P. Sutherland, J. Huo, S. Xu, F. Mackay, and K. P. Lam. 2006. BAFF costimulation of Toll-like receptor-activated B-1 cells. Eur. J. Immunol. 36: 1837-1846.
49. Castigli, E., S. A. Wilson, S. Scott, F. Dedeoglu, S. Xu, K. P. Lam, R. J. Brum, H. Jabara, and R. S. Geha. 2005. TACI and BAFF-R mediate isotype switching in B cells. J. Exp. Med. 201: 35-39.
50. He, B., A. Chadburn, E. Jou, E. J. Schattner, D. M. Knowles, and A. Cerutti. 2004. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J. Immunol. 172: 3268-3279.
51. Hatada, E. N., R. K. Do, A. Orlofsky, H. C. Liou, M. Prystowsky, I. C. MacLennan, J. Caamano, and S. Chen-Kiang. 2003. NF-κB1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-κB2 p100 to p52 in quiescent mature B cells. J. Immunol. 171: 761-768.
52. Enzler, T., G. Bonizzi, G. J. Silverman, D. C. Otero, G. F. Widhopf, A. Anzelon-Mills, R. C. Rickert, and M. Karin. 2006. Alternative and classical NF-κB signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity 25: 403-415.
53. Bonizzi, G., M. Bebien, D. C. Otero, K. E. Johnson-Vroom, Y. Cao, D. Vu, A. G. Jegga, B. J. Aronow, G. Ghosh, R. C. Rickert, and M. Karin. 2004. Activation of IKKα target genes depends on recognition of specific κB binding sites by RelB:p52 dimers. EMBO J. 23: 4202-4210.
54. Leung, T. H., A. Hoffmann, and D. Baltimore. 2004. One nucleotide in a κB site can determine cofactor specificity for NF-κB dimers. Cell 118: 453-464.
55. Castigli, E., S. A. Wilson, L. Garibyan, R. Rachid, F. Bonilla, L. Schneider, and R. S. Geha. 2005. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat. Genet. 37: 829-834.
56. Salzer, U., H. M. Chapel, A. D. Webster, Q. Pan-Hammarström, A. Schmitt-Graeff, M. Schlesier, H. H. Peter, J. K. Rockstroh, P. Schneider, A. A. Schäffer, et al. 2005. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat. Genet. 37: 820-828.
57. Salzer, U., and B. Grimbacher. 2006. Common variable immunodeficiency: the power of co-stimulation. Semin. Immunol. 18: 337-346.